These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1339 related articles for article (PubMed ID: 11801466)

  • 1. Periodic morphologic, cytogenetic and clonality evaluation after autologous peripheral blood progenitor cell transplantation in patients with lymphoproliferative malignancies.
    Laurenti L; Chiusolo P; Garzia MG; Zini G; Sorà F; Piccirillo N; Piccioni P; Zollino M; Leone G; Sica S
    Haematologica; 2002 Jan; 87(1):59-66. PubMed ID: 11801466
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and characterization of secondary myelodysplastic syndromes following autologous transplantation.
    Del Cañizo Mf; Amigo Mf; Hernández JM; Sanz G; Núñez R; Carreras E; Alegre A; Cuesta B; Mataix R
    Haematologica; 2000 Apr; 85(4):403-9. PubMed ID: 10756367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosomal abnormalities in women with breast cancer after autologous stem cell transplantation are infrequent and may not predict development of therapy-related leukemia or myelodysplastic syndrome.
    Martínez-Climent JA; Comes AM; Vizcarra E; Benet I; Arbona C; Prósper F; Solano C; García Clavel B; Marugán I; Lluch A; García-Conde J
    Bone Marrow Transplant; 2000 Jun; 25(11):1203-8. PubMed ID: 10849534
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physician Education: Myelodysplastic Syndrome.
    Yoshida Y
    Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary acute myeloid leukemia and myelodysplasia after autologous peripheral blood progenitor cell transplantation.
    Sevilla J; Rodríguez A; Hernández-Maraver D; de Bustos G; Aguado J; Ojeda E; Arrieta R; Hernández-Navarro F
    Ann Hematol; 2002 Jan; 81(1):11-5. PubMed ID: 11807629
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Longitudinal assessment of hematopoietic abnormalities after autologous hematopoietic cell transplantation for lymphoma.
    Bhatia R; Van Heijzen K; Palmer A; Komiya A; Slovak ML; Chang KL; Fung H; Krishnan A; Molina A; Nademanee A; O'Donnell M; Popplewell L; Rodriguez R; Forman SJ; Bhatia S
    J Clin Oncol; 2005 Sep; 23(27):6699-711. PubMed ID: 16170178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
    Kanteti R; Miller K; McCann J; Roitman D; Morelli J; Hurley C; Berkman E; Schenkein D
    Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplasia and acute leukemia following high-dose chemotherapy and autologous bone marrow or peripheral blood stem cell transplantation.
    Sobecks RM; Le Beau MM; Anastasi J; Williams SF
    Bone Marrow Transplant; 1999 Jun; 23(11):1161-5. PubMed ID: 10382956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune reconstitution after autologous hematopoietic stem cell transplantation in relation to underlying disease, type of high-dose therapy and infectious complications.
    Steingrimsdottir H; Gruber A; Björkholm M; Svensson A; Hansson M
    Haematologica; 2000 Aug; 85(8):832-8. PubMed ID: 10942930
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Abnormal cytogenetics predict poor survival after high-dose therapy and autologous blood cell transplantation in multiple myeloma.
    Rajkumar S; Fonseca R; Lacy M; Witzig T; Lust J; Greipp P; Therneau T; Kyle R; Litzow M; Gertz M
    Bone Marrow Transplant; 1999 Sep; 24(5):497-503. PubMed ID: 10482933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous stem cell transplantation for high-risk Hodgkin's disease: improvement over time and impact of conditioning regimen.
    Subirà M; Sureda A; Martino R; García J; Altés A; Canals C; Domingo-Albós A; Brunet S; Sierra J
    Haematologica; 2000 Feb; 85(2):167-72. PubMed ID: 10681724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
    Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
    Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Late non-relapse mortality among adult autologous stem cell transplant recipients: a nation-wide analysis of 1,482 patients transplanted in 1990-2003.
    Jantunen E; Itälä M; Siitonen T; Koivunen E; Leppä S; Juvonen E; Kuittinen O; Lehtinen T; Koistinen P; Nyman H; Nousiainen T; Volin L; Remes K
    Eur J Haematol; 2006 Aug; 77(2):114-9. PubMed ID: 16856906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of preparatory regimen and source of hematopoietic cells on outcome of autotransplantation for non-Hodgkin's lymphoma.
    Stockerl-Goldstein KE; Horning SJ; Negrin RS; Chao NJ; Hu WW; Long GD; Hoppe RT; Amylon MD; Brown BW; Wong RM; Blume KG
    Biol Blood Marrow Transplant; 1996 May; 2(2):76-85. PubMed ID: 9118302
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of hematological and immunological function during long-term follow-up after peripheral blood stem cell transplantation.
    Laurenti L; Sica S; Salutari P; Rutella S; Serafini R; D'Onofrio G; Rumi C; Leone G
    Haematologica; 1998 Feb; 83(2):138-42. PubMed ID: 9549925
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
    Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
    Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Secondary myelodysplastic syndrome and acute myelogenous leukemia are significant complications following autologous stem cell transplantation for lymphoma.
    Howe R; Micallef IN; Inwards DJ; Ansell SM; Dewald GW; Dispenzieri A; Gastineau DA; Gertz MA; Geyer SM; Hanson CA; Lacy MQ; Tefferi A; Litzow MR
    Bone Marrow Transplant; 2003 Aug; 32(3):317-24. PubMed ID: 12858205
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acute erythroid neoplastic proliferations. A biological study based on 62 patients.
    Domingo-Claros A; Larriba I; Rozman M; Irriguible D; Vallespí T; Aventin A; Ayats R; Millá F; Solé F; Florensa L; Gallart M; Tuset E; Lopez C; Woessner S
    Haematologica; 2002 Feb; 87(2):148-53. PubMed ID: 11836165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Secondary myeloid leukemia and myelodysplastic syndromes in patients treated for Hodgkin's disease: a report from the German Hodgkin's Lymphoma Study Group.
    Josting A; Wiedenmann S; Franklin J; May M; Sieber M; Wolf J; Engert A; Diehl V;
    J Clin Oncol; 2003 Sep; 21(18):3440-6. PubMed ID: 12668650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 67.